Healthcare / BiotechnologyNasdaqCM
$8.36
-0.56 (-6.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-5.4M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
0.1x
↓EV/EBITDA
N/A
•ROE
-212.6%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-12.5M · FCF $-5.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | — | — | — | — | — | $1.8M | $5.2M | $3.5M | $2.0M | $1.3M | $1.0M | $0.00 | $0.00 |
| Net Income | $-12.5M | $-12.5M | $-5.6M | $-12.5M | $-31.6M | $-12.8M | $-7.4M | $-6.9M | $-1.7M | $-34.4M | $-39.5M | $-29.1M | $-8.0M |
| EBITDA | $-12.6M | $-12.6M | $-5.7M | $-12.9M | $-23.0M | $-12.8M | $-7.8M | $-8.1M | $-1.7M | — | — | — | — |
| EPS | -129.10 | -129.10 | -1043.10 | -5533.20 | -21427.20 | -11116.80 | -18000.00 | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | -696.3% | -148.8% | -238.5% | -86.3% | -2724.6% | -3946.5% | — | — |
| Net Margin | — | — | — | — | — | -693.8% | -140.5% | -200.2% | -85.6% | -2701.7% | -3907.6% | — | — |
| Balance Sheet | |||||||||||||
| Debt/Equity | — | — | 0.15 | 0.05 | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.84 | 1.84 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-5.4M | $-5.4M | $-4.5M | $-12.8M | $-19.1M | $-10.2M | $-10.3M | $-11.6M | $4.2M | $-27.8M | $-32.6M | $-21.0M | $-6.6M |
| Returns | |||||||||||||
| ROE | -212.6% | -212.6% | -368.8% | -237.2% | -304.4% | -33.0% | -33.2% | -65.6% | 131.4% | 1187.2% | -66.6% | -31.6% | 122.5% |
| Valuation | |||||||||||||
| P/E | 0.08 | 0.08 | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.14 | 0.14 | 1.08 | 0.40 | 0.42 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| Revenue Growth | — | — | — | — | — | -64.8% | 51.0% | 77.6% | 53.1% | 26.1% | — | — | — |
| EPS Growth | 87.6% | 87.6% | 81.1% | 74.2% | — | 38.2% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-93.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1043.10 → -129.10
Residual
-93.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.